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A B S T R A C T   
Purpose: To report the outcomes of two cases of infectious scleritis with severe scleral thinning managed using 
combined mechanical debridement, cryopreserved umbilical amnion (UA) and amniotic membrane (AM) grafts, 
and antimicrobial therapy. 
Observations: Two patients presented with severe infectious scleritis with progressive scleral melts secondary to 
Pseudomonas aeruginosa subsequent to pterygium surgery and intravitreal injection, respectively. Surgical 
debridement was followed by UA grafting, AM transplantation, and antimicrobial therapy. Epithelialization and 
vascularization were seen within 1–4 weeks post-operatively. At last follow up of 5–6 months, the structural 
integrity of the sclera remained preserved with no infection recurrence, graft necrosis, or wound dehiscence. 
Conclusions and importance: This case series highlights the utilization of UA grafting along with AM trans-
plantation and topical and systemic antibiotics to preserve the globe in cases of severe infectious scleritis.   
1. Introduction 
Infection is a serious but rare cause of scleritis, representing about 
5–10% of all scleritis cases.1 Infectious scleritis (IS) is associated with 
longer resolution times and worse outcomes compared to non-infectious 
causes,2 and can result in a number of vision-threatening complications 
including cataracts, glaucoma, endophthalmitis, and loss of the globe.3,4 
Topical and systemic antibiotic regimens alone are often inadequate, as 
the biofilm, avascularity of the sclera, and dense collagen network limit 
antibiotic penetration and reduce bacterial susceptibility.5,6 Thus, sur-
gical debridement is often used to facilitate antibiotic access.3,7,8 
A number of studies have reported favorable outcomes using 
debridement in conjunction with antibiotics for the treatment of IS.4,5,7 
In cases with severe thinning, a patch graft is often used to help maintain 
structural integrity of the globe. Umbilical amnion (UA) and amniotic 
membrane (AM) grafts have been used extensively in ophthal-
mology,9,10 however, their use in the treatment of IS and for severe 
scleral thinning has not been reported. Herein, we describe two cases of 
IS that were successfully treated with mechanical debridement, UA 
grafting and AM transplantation, and antimicrobial therapy. 
2. Findings 
2.1. Case 1 
A 73-year-old man presented with persistent pain OS despite treat-
ment with topical antibiotics for approximately 2 weeks. He had a his-
tory of pterygium surgery with mitomycin-C in this eye 5 years prior. 
The visual acuity was 20/200 and intraocular pressure (IOP) was 11 
mmHg. Examination revealed 9 mm × 5 mm scleral necrosis nasally 
with purulent material and scleral plaques. There was significant scleral 
thinning with uveal show but no uveal prolapse (Fig. 1). There was also a 
temporal scleral plaque without active scleral necrosis. The patient had 
inferior keratic precipitates (KPs) and 2+ nuclear sclerosis (NS). The 
diagnosis was confirmed to be infectious scleritis with cultures growing 
Pseudomonas aeruginosa. 
The patient was taken to the operating room. Toothed forceps and a 
57-blade were used to carefully dissect the nasal scleral plaque, for 
which pathologic evaluation demonstrated dense calcification. The 
necrotic scleral material was then debrided with a 57-blade and sent for 
additional cultures. Dilute ceftriaxone was used to wash out the area of 
necrotic sclera. A 0.75 cm × 1.0 cm UA patch graft (AmnioGuard; Bio- 
Tissue, Miami, FL) was placed over the area of scleral thinning and 
* Corresponding author. Sidney Kimmel Medical College at Thomas Jefferson University, Cornea Service, Wills Eye Hospital, 840 Walnut Street, Suite 920, 
Philadelphia, PA, 19107, USA. 
E-mail address: zsyed@willseye.org (Z.A. Syed).  
Contents lists available at ScienceDirect 
American Journal of Ophthalmology Case Reports 
journal homepage: www.ajocasereports.com/ 
https://doi.org/10.1016/j.ajoc.2021.101013 
Received 16 June 2020; Received in revised form 13 October 2020; Accepted 11 January 2021   
American Journal of Ophthalmology Case Reports 21 (2021) 101013
2
secured into place using 16 interrupted 7-0 Vicryl sutures. The graft was 
trimmed at the edges so that it was flush with the edge of the corneal 
limbus. Next, a 2.5 cm × 2.0 cm AM (AmnioGraft; Bio-Tissue, Miami, FL) 
was cut in half. The first half was placed over the UA patch graft, and 
was secured in place with Tisseel fibrin glue (Baxter, Deerfield, IL). The 
other half was placed over the first AM and secured with 4 interrupted 7- 
0 Vicryl sutures at the corners of the graft. Subconjunctival aliquots of 
ceftriaxone were administered surrounding the area of infection, and the 
eye was patched and shielded. Post-operative drop regimen included 
fortified tobramycin 14 mg/ml and topical moxifloxacin 0.5% every 2 h 
with a taper over six weeks, oral ciprofloxacin 500 mg twice daily for 
four weeks, and cyclopentolate 1% twice daily for six weeks. Topical 
prednisolone acetate 1% four times daily was started three weeks after 
surgery and was tapered off over the ensuing 10 weeks. 
On post-operative day 1, the patient’s vision was 20/300. The UA 
with overlying AM remained in good position. Slit lamp examination 
revealed 3+ conjunctival injection, inferior KPs, a small hyphema, and 
2+ NS. At 1 week, the visual acuity was counting fingers due to wors-
ening of the cataract, and IOP was 8 mmHg. Examination revealed that 
the UA remained in good position with staining inferiorly and dissolu-
tion of the overlying AMs. There was 3+ conjunctival injection diffusely, 
a chemotic plica, an area of depression between the plica and border of 
the AM graft, inferior KPs, a sliver hyphema, and 2–3+ brunescent NS. 
By 1 month, the visual acuity remained at counting fingers, and IOP was 
10 mmHg. Examination revealed similar findings as 1 week, however 
the UA showed early vascularization with no staining present. The 
conjunctival inflammation had decreased to 2+ injection and hyphema 
had resolved. At 3 months, visual acuity had slightly improved to 20/ 
400, and IOP was 12 mmHg. Examination revealed that the UA had 
dissolved with residual vascularization and no staining, a quiet con-
junctiva, cornea with no infiltrate or epithelial defect, and 3+ brunes-
cent NS with pigment on the anterior capsule (Fig. 1). Six months post- 
operatively, the patient underwent cataract extraction with intraocular 
lens placement. His 1-week post-operative visual acuity was 20/40. 
2.2. Case 2 
A 64-year-old female was referred to the Wills Eye Hospital Emer-
gency Room for a culture-positive infectious corneal ulcer secondary to 
Pseudomonas aeruginosa that had failed topical antibiotics and had pro-
gressed to suspected endophthalmitis. The patient underwent an intra-
vitreal tap and injection for presumed keratitis-related endophthalmitis, 
and subsequently developed scleritis two weeks later in the location of 
the intravitreal injection, at which point she was referred to our practice. 
The visual acuity was hand motion and IOP was 4 mmHg. Slit lamp 
examination was notable for a 4 mm × 6.5 mm inferotemporal scleral 
abscess that was non-contiguous with the cornea, a diffusely edematous 
corneal stroma with patchy tissue loss (ranging from 40 to 80%), a 9 
mm × 10 mm corneal epithelial defect, and a 3.5 mm hypopyon (Fig. 2). 
The patient was taken to the operating room for corneal biopsy and a 
single-layer AM graft covering the involved sclera, with injection of 
subconjunctival cefazolin 50 mg/ml and gentamicin 40 mg/ml. Despite 
this intervention and inpatient treatment with intravenous levofloxacin 
750 mg daily and hourly topical fortified tobramycin 14 mg/ml and 
topical moxifloxacin 0.5% for seven days, the patient had progressive 
scleral melt and was taken to the operating room for more definitive 
surgery. 
The surgery was performed similar to that described for Case 1. The 
necrotic inferotemporal scleral material was resected and sent for pa-
thology evaluation. The area of scleral necrosis was measured to be 5 
mm × 9 mm, and a UA patch graft was cut to size and secured with 
interrupted 9-0 Vicryl sutures. A 8 mm × 12 mm AM graft was then 
placed over this area, secured with Tisseel fibrin glue, and sutured on all 
sides with interrupted 7-0 Vicryl sutures. The corneal defect was then 
addressed by applying a 10 mm x 10 mm AM fixated with Tisseel fibrin 
glue. A second layer of 18 mm × 15 mm AM was then placed over the 
first layer and sutured into place with interrupted 9-0 Vicryl sutures in a 
mattress fashion. A subconjunctival injection of ceftriaxone was 
administered inferotemporally and the eye was patched and shielded. 
Post-operative regimen included topical fortified tobramycin 14 mg/ml 
and topical moxifloxacin 0.5% every 2 h with a taper over six weeks, 
ciprofloxacin ophthalmic ointment four times a day for four months, 
oral moxifloxacin 400 mg daily for four weeks, atropine 1% twice daily 
for six weeks, and topical prednisolone acetate 1% twice daily with a 
taper over four months. 
At post-operative day 1, the visual acuity was light perception, and 
IOP was 3 mmHg. Exam revealed 2+ conjunctival injection, scleral 
thinning inferotemporally covered by UA and AM, cornea with a 9 mm 
× 8 mm epithelial defect covered with double-layered AM in good po-
sition, and a hazy view beyond the cornea. At 1 week, visual acuity 
remained light perception and IOP was 2 mmHg. Examination revealed 
2+ conjunctival injection, UA in good position inferotemporally 
covering the scleral thinning, and a 4 mm × 4.5 mm corneal epithelial 
defect with ~50% thinning centrally. At 2 weeks post-operatively, the 
entire ocular surface was fully epithelialized. By 1 month, vision was HM 
and IOP was 2 mmHg. Examination revealed 2+ conjunctival injection, 
and the area with UA was well vascularized. The cornea had diffuse 
edema, a scar paracentrally, and irregular thinning (greatest ~50% loss 
nasally). At 5 months, examination revealed a white and quiet con-
junctiva, well vascularized area previously covered by UA, and similar 
corneal findings (Fig. 2). The visual acuity reverted back to light 
perception, and the patient was confirmed to have an afferent pupillary 
defect. At this point, treatment options including penetrating kerato-
plasty and Boston Keratoprosthesis were discussed with the patient, 
however given the poor visual prognosis, the patient preferred 
observation. 
3. Discussion 
Bacterial etiologies comprise the majority of IS cases, with Pseudo-
monas aeruginosa being the most common infectious agent.3 Bacterial 
invasion is facilitated by proteinases that degrade the basement 
Fig. 1. Case 1. Patient presented with 9 mm × 5 mm scleral melt (A) that was surgically managed using umbilical amnion patch grafting and amniotic membrane 
transplantation. Post-operative photos after 1 day (B), 1 month (C), and 3 months (D) are presented. 
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membrane and cause cell lysis as well as exotoxins that cause stromal 
necrosis.11,12 Furthermore, host lysosomal enzymes and oxidative sub-
stances produced by neutrophils, keratocytes, and epithelial cells may 
significantly contribute to the destruction caused by Pseudomonas aer-
uginosa.13 This infectious assault and resulting inflammation can even-
tually lead to scleral ischemia, necrosis, and thinning. 
In less than 20% of cases of IS, medical therapy alone (including 
systemic, topical, and subconjunctival antibiotics) results in complete 
resolution of infection. There are several possible explanations for this 
relatively low success rate, including the sclera’s dense collagen fibers 
and avascularity. As a result, surgical debridement is often used 
adjunctively to decrease the microbial load and improved antibiotic 
delivery.4,14 Early mechanical debridement combined with antimicro-
bial therapy has been demonstrated to decrease the length of treatment, 
increase the rates of globe preservation, and improve prognosis for 
IS.4,14–16 Although well-described in the literature as an effective sur-
gical technique for infectious scleritis,17 cryotherapy was not utilized in 
either of these cases due to the severe degree of scleral thinning and 
concerns that cryotherapy may increase the risk of perforation. 
In this case series, mechanical debridement, UA and AM grafting, 
and antimicrobial therapy successfully preserved the globe in two cases 
of necrotizing IS and scleral melt. Case 1 developed IS after pterygium 
surgery using mitomycin-C and Case 2 developed IS secondary to an 
intravitreal injection for presumed keratitis-associated endophthalmitis. 
Scleral melting and IS are well reported complications following pte-
rygium surgery.5–7 In one series including three cases of Pseudomona-
s-associated keratoscleritis occurring after pterygium excision, early 
debridement, topical and systemic antibiotics, and low-dose oral pred-
nisone resulted in successful outcomes.18 On the other hand, there has 
only been one prior report of necrotizing IS following intravitreal in-
jection,19 but several reports of IS following sub-Tenon injection.20–22 
This highlights the fact that although rare, ocular injection can result in 
IS and severe complications such as scleral melt. Case 1 had visual re-
covery following cataract surgery, whereas Case 2 did not regain func-
tional vision following our surgical treatment; this latter case had an 
afferent pupillary defect along with presenting visual acuity worse than 
20/200 vision and endophthalmitis, which are known poor prognostic 
indicators in IS.5 
Various tissues and materials have been used to cover the sclera 
following debridement of large areas.23 While AM transplantation has 
been employed in the treatment of IS, most reports involve the use of 
various tissue grafts in conjunction with AM. Zheng et al.24 successfully 
used fascia lata grafts in conjunction with AM following surgical 
debridement for IS, and Siatiri et al.25 restored globe integrity and 
treated inflammation in a case of necrotizing IS caused by Pseudomonas 
aeruginosa using debridement, scleral graft, tenonplasty, and AM trans-
plantation. Finger et al. described the use of super-thick amniotic 
membrane grafts for ocular surface reconstruction after resection of 
conjunctival melanoma, squamous cell carcinoma, sebaceous carci-
noma, and atypical pterygium, and for scleral necrosis; retention and 
complete epithelialization were achieved in all cases.10 In the present 
case series, a thick layer of UA was used to cover the sclera which was 
then covered with thinner AM. 
Anatomically, the UA contains the AM as its outer layer and a loose, 
proteoglycan-rich Wharton’s jelly as its inner layer. Both the UA and AM 
contain collagen, fibronectin, glycosaminoglycans, and HC-HA/PTX3, 
however UA is about 10 times thicker than AM alone.26–28 The UA is 
advantageous compared to other tissue and synthetic materials (such as 
sclera, cornea, dermis, and autologous fascia lata) because it is readily 
available off-the-shelf, is relatively transparent for good cosmetic out-
comes, is relatively thick and flexible for secure handling, suturability, 
and filling voids, has low immunogenicity, and has anti-inflammatory, 
anti-scarring, and pro-regenerative properties. Hence, UA may prevent 
the ongoing necrotic process by reducing infiltration and inducing 
apoptosis of activated neutrophils29,30 and macrophages.31–33 Addi-
tionally, one key biological modulator present in both UA and AM, 
HC-HA/PTX3, upregulates IL-10, downregulates IL-12, and polarizes 
macrophages toward anti-inflammatory phenotype, all of which play an 
integral role in the healing process.26–28 Moreover, the UA used in our 
cases was well vascularized within 1 month of surgery, a feature which 
prevents infection and further thinning. Such an effect has also been 
shown in cutaneous wounds.34–38 Together these conditions may pro-
vide an optimal healing environment and facilitate recovery of an 
inflamed ocular surface as shown in these cases. 
4. Conclusions 
This case series highlights the utilization of UA to maintain the 
scleral integrity and, along with AM transplantation and antibiotics, 
preserve the globe in cases of severe IS. 
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Fig. 2. Case 2. Patient presented with a 4 mm × 6.5 mm inferotemporal scleral abscess, a 9 mm × 10 mm corneal epithelial defect, and a 3.5 mm hypopyon (A, E). 
Surgical intervention resulted in progressive healing and epithelialization at 1 day (B, F) and 1 week (C, G), with complete epithelialization at 8 weeks (D, H). 
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13. Steuhl KP, Döring G, Henni A, Thiel HJ, Botzenhart K. Relevance of host-derived and 
bacterial factors in Pseudomonas aeruginosa corneal infections. Invest Ophthalmol 
Vis Sci. 1987;28(9):1559–1568. 
14. Lin CP, Shih MH, Tsai MC. Clinical experiences of infectious scleral ulceration: a 
complication of pterygium operation. Br J Ophthalmol. 1997;81(11):980–983. 
15. Ahmad S, Lopez M, Attala M, et al. Interventions and outcomes in patients with 
infectious Pseudomonas scleritis: a 10-year perspective. Ocul Immunol Inflamm. 
2019;27(3):499–506. 
16. Huang FC, Huang SP, Tseng SH. Management of infectious scleritis after pterygium 
excision. Cornea. 2000;19(1):34–39. 
17. Reynolds MG, Alfonso E. Treatment of infectious scleritis and keratoscleritis. Am J 
Ophthalmol. 1991;112(5):543–547. 
18. Huang SC, Lai HC, Lai IC. The treatment of Pseudomonas keratoscleritis after 
pterygium excision. Cornea. 1999;18(5):608–611. 
19. Coussa RG, Wakil SM, Saheb H, Lederer DE, Oliver KM, Cheema DP. Anterior 
infectious necrotizing scleritis secondary to Pseudomonas aeruginosa infection 
following intravitreal ranibizumab injection. American journal of ophthalmology case 
reports. 2017;5:16–19. 
20. Agarwal M, Ranjan R, Mathur U. Necrotic scleral melt and fungal keratitis-a 
complication of subtenon triamcinolone acetonide injection. Journal of ophthalmic 
inflammation and infection. 2020;10(1):3. 
21. Gharaee H, Khalife M, Poor SS, Abrishami M. Infectious scleritis after subtenon 
triamcinolone acetonide injection. Ocul Immunol Inflamm. 2011;19(4):284–285. 
22. Seth RK, Gaudio PA. Nocardia asteroides necrotizing scleritis associated with 
subtenon triamcinolone acetonide injection. Ocul Immunol Inflamm. 2008;16(4): 
139–140. 
23. Ramenaden ER, Raiji VR. Clinical characteristics and visual outcomes in infectious 
scleritis: a review. Clin Ophthalmol. 2013;7:2113–2122. 
24. Zheng X, Kodama T, Goto T, Ohashi Y. Autologous fascia lata grafts for scleral repair 
in eyes with infectious necrotizing scleritis. Arch Ophthalmol. 2011;129(9): 
1225–1227. 
25. Siatiri H, Mirzaee-Rad N, Aggarwal S, Kheirkhah A. Combined tenonplasty and 
scleral graft for refractory Pseudomonas scleritis following pterygium removal with 
mitomycin C application. J Ophthalmic Vis Res. 2018;13(2):200–202. 
26. He H, Li W, Tseng DY, et al. Biochemical characterization and function of complexes 
formed by hyaluronan and the heavy chains of inter-alpha-inhibitor (HC*HA) 
purified from extracts of human amniotic membrane. J Biol Chem. 2009;284(30): 
20136–20146. 
27. He H, Zhang S, Tighe S, Son J, Tseng SC. Immobilized heavy chain-hyaluronic acid 
polarizes lipopolysaccharide-activated macrophages toward M2 phenotype. J Biol 
Chem. 2013;288(36):25792–25803. 
28. Koh TJ, DiPietro LA. Inflammation and wound healing: the role of the macrophage. 
Expet Rev Mol Med. 2011;13:e23. 
29. Park WC, Tseng SC. Modulation of acute inflammation and keratocyte death by 
suturing, blood, and amniotic membrane in PRK. Invest Ophthalmol Vis Sci. 2000;41 
(10):2906–2914. 
30. Wang MX, Gray TB, Park WC, et al. Reduction in corneal haze and apoptosis by 
amniotic membrane matrix in excimer laser photoablation in rabbits. J Cataract 
Refract Surg. 2001;27(2):310–319. 
31. Shimmura S, Shimazaki J, Ohashi Y, Tsubota K. Antiinflammatory effects of 
amniotic membrane transplantation in ocular surface disorders. Cornea. 2001;20(4): 
408–413. 
32. Bauer D, Wasmuth S, Hermans P, et al. On the influence of neutrophils in corneas 
with necrotizing HSV-1 keratitis following amniotic membrane transplantation. Exp 
Eye Res. 2007;85(3):335–345. 
33. Heiligenhaus A, Bauer D, Meller D, Steuhl KP, Tseng SC. Improvement of HSV-1 
necrotizing keratitis with amniotic membrane transplantation. Invest Ophthalmol Vis 
Sci. 2001;42(9):1969–1974. 
34. Caputo WJ, Vaquero C, Monterosa A, et al. A retrospective study of cryopreserved 
umbilical cord as an adjunctive therapy to promote the healing of chronic, complex 
foot ulcers with underlying osteomyelitis. Wound Repair Regen. 2016;24(5): 
885–893. 
35. Raphael A. A single-centre, retrospective study of cryopreserved umbilical cord/ 
amniotic membrane tissue for the treatment of diabetic foot ulcers. J Wound Care. 
2016;25(Suppl 7):S10–S17. 
36. Raphael A, Gonzales J. Use of cryopreserved umbilical cord with negative pressure 
wound therapy for complex diabetic ulcers with osteomyelitis. J Wound Care. 2017; 
26(Sup10):S38–S44. 
37. Couture M. A single-center, retrospective study of cryopreserved umbilical cord for 
wound healing in patients suffering from chronic wounds of the foot and ankle. 
Wounds. 2016;28(7):217–225. 
38. Bemenderfer TB, Anderson RB, Odum SM, Davis WH. Effects of cryopreserved 
amniotic membrane-umbilical cord allograft on total ankle arthroplasty wound 
healing. J Foot Ankle Surg : official publication of the American College of Foot and 
Ankle Surgeons. 2019;58(1):97–102. 
Z.A. Syed and C.J. Rapuano                                                                                                                                                                                                                 
